Media

Latest News

PIQUR Receives Orphan Drug Designation from FDA for PQR309 in PCNSL

December 2, 2016

PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to PIQUR’s lead compound PQR309 for the...

Read More

PIQUR raises CHF 18 Million in Series A2 financing

July 16, 2016

PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative anti-cancer drugs based on PI3K and mTOR inhibition, today announced the closing of an...

Read More

Eisai and PIQUR sign landmark collaboration agreement to investigate Halaven® (eribulin) and PQR309 in hard to treat form of breast cancer

February 17, 2016

Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor in patients with triple negative breast cancer Hatfield, UK and Basel, Switzerland, 17 February 2016 – Eisai and PIQUR Therapeutics...

Read More

PIQUR’s oncology advisor, Josep Tabernero, to serve as ESMO President 2018-2019

August 31, 2015

The European Society for Medical Oncology (ESMO), the leading pan-European organisation in medical oncology, announced that the President for the 2018-2019 period will be Josep Tabernero, Head of the Medical...

Read More

PIQUR named the best start-up in Switzerland

June 5, 2015

The pharmaceutical company wins the 2015 SEF.Award in the “High-tech/Biotech” category PIQUR has been named the winner of the 2015 Swiss Economic Award in the “High-tech/Biotech” category. Today, at the...

Read More

PIQUR announces positive Phase 1 study results and the start of Phase 2 of PQR309

May 27, 2015

Study confirms that PQR309 is well tolerated and shows promising signs of clinical antitumor activity Please find PDF versions of the release here (German) and here (English). PIQUR Therapeutics AG, a Swiss clinical-stage...

Read More

Congratulations to Michael Hall, Winner of the prestigious “Canada Gairdner International Award”

May 25, 2015

PIQUR Therapeutics AG congratulates Scientific Advisory Board Member, Michael Hall on winning the prestigious “Canada Gairdner International Award”.  On 25 March 2015, the five winners of this year’s “Canada Gairdner...

Read More

PIQUR to present posters on its lead compound PQR309 at AACR Annual Meeting 2015

April 17, 2015

Initial clinical results confirm that PQR309 is well tolerated and shows first signs of clinical antitumor activity PIQUR Therapeutics AG today announced that the company and its academic collaborators will...

Read More